RxDoctor Payments Data

Shane Nau, MD

Ophthalmology · Littleton, CONPI 1861952285

Payments from drug & device makers

$1,514in general payments, 2019–2025

Across 33 payments — averaging $45.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sight Sciences, Inc.$462
  • Alcon$370
  • NEW World Medical,inc.$177
  • Regeneron Healthcare Solutions, Inc.$166
  • Sun Pharmaceutical Industries Inc.$141
  • Harrow Eye, LLC$36
  • plus $163 from 7 others

What the payments were for

  • Food & beverage$1,514100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,514 in reported general payments places this provider in the 55th percentile of 262 ophthalmology providers in Colorado.

See all ophthalmology providers in Colorado

Medicare billing

Part B allowed, 2024
$866,444
Medicare patients
768
Services billed
5,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XdemvyLotilaner13$25,205
RestasisCyclosporine21$23,624
Fluorometholone124$13,143
VevyeCyclosporine11$8,477
Prednisolone Acetate79$5,154
Ketorolac Tromethamine85$3,243
Latanoprost202$2,190
MoxifloxacinMoxifloxacin Hcl74$2,055
ErythromycinErythromycin Base111$1,664
Neomycin-Polymyxin-DexamethNeomycin/Polymyxin B/Dexametha118$1,423
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat45$767
Dorzolamide Hcl19$386
Brimonidine Tartrate27$353
Timolol Maleate21$220

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Tarsus Pharmaceuticals, Inc.Xdemvy$27$25,20513 claims
AbbVieRestasis$15$23,62421 claims
Harrow Eye, LLCVevye$36$8,47711 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 262 ophthalmology providers in Colorado.

Other ophthalmology in Littleton

See the full list for Colorado

Where these figures come from

Is this you, or does something look wrong? →